We use cookies to keep our website secure, personalize your experience and for web analytics purposes. Read our Privacy Policy to learn more. By clicking Accept, you agree to our use of cookies.
With digitization moving at an incredible pace, the last decades can be justly called the golden era for healthcare and pharma companies. And when it comes to technologies, Artificial Intelligence and Machine Learning are game changers.
Here are some statistics testifying to that point as well:
According to ‘Artificial Intelligence (AI) In Drug Discovery Global Market Report 2022, By Technology, By Drug Type, By Therapeutic Type, By End-Users’ report, the global Artificial Intelligence (AI) in Drug Discovery Market is estimated to be worth $2994.5 million by 2026 with IBM Corporation, Microsoft, Atomwise Inc., Deep Genomics, Cloud Pharmaceuticals, and other well-known tech companies leading the movement.
In our article, we will observe the advancements that AI brings to drug development, reveal the organizations’ key challenges while adopting AI tools, provide ways of facing them and dig deeper into some popular use cases of AI in the pharmaceutical products lifecycle.
The impact of AI on drug development can be considered revolutionary, primarily because of its ability to significantly reduce the usual drug design timeframes and expand the current drug discovery scale.
Here are four key benefits of AI in drug development:
AI is an objective science. It means the AI-based drug development process is not a subject of prejudice, existing knowledge, personal interests or anything else that can directly impact the development outputs.
Besides assisting humans with mundane tasks, AI leverages the latest technologies in biology and computing. This process is ever-evolving, and with increasing powers of innovation and the reduction of costs of AI tools, AI plays a vital role in drug development advancements now and in future.
In drug screenings, the enhanced predictivity power of AI tools positively impacts the process of defining meaningful interactions. Therefore, a thorough and meticulous approach to parameters’ design can significantly reduce false positives.
With the help of a virtual lab, drug screening outputs can be streamlined, thus significantly reducing human resources hours.
Despite the growing interest in AI and the technology’s great potential, there are still a number of challenges that healthcare organizations face when it comes to implementing AI.
The overall success of the AI initiatives is closely tied to an enormous amount of data leveraged for AI systems’ training. There are 2 potential pitfalls lying in the data management process, i.e.:
AI-based systems require highly qualified personnel, which also incurs additional costs.
Despite AI evangelists’ profound claims about AI and ML adding value to human work, the heated debate on whether AI can take away human jobs never seems to end. Another hot topic is a black box phenomenon, i.e. the issue with the visibility of the processes and workings in between the inputs and outputs.
Though the above mentioned challenges seem hard to overcome, each has quite straightforward solutions.
The data management and the lack of talent issues can be solved only if an organization sees clear benefits of the AI implementation and is ready to set the right priorities to reach maximum operational efficiency. As for the black box phenomenon, this concern can be addressed with the help of explainable AI, i.e. the system where the entire process of AI workings is straightforward and easy to understand for humans.
The role of AI in drug development cannot be underestimated. One of the main criteria that help to measure the impact is that AI can be applied through the whole lifecycle of pharmaceutical products.
Basically, the use cases of AI in drug development can be broken down into the following categories (with examples of AI application):
Below we will provide several use cases from some of the categories listed above.
Preventing a drug’s toxic effects is impossible without predicting a drug molecule’s toxicity. One of the examples of such kind of predictions is the DeepTox machine learning algorithm which was able to:
Numerous proteins directly impact the disease progression. Thus, predicting the target protein’s structure is vital while developing the drug molecule. In structure-based drug development, AI may become a helpful tool since it can predict 3D protein structure. A good example of such AI tool leverage is the AlphaFold AI tool. AlphaFold was able to:
AI tools are widely used in drug manufacturing. E.g. DEM AI tool streamlines the manufacturing process by:
Numerous AI tools are used to regulate the in-line manufacturing processes. The artificial neural network uses several algorithms such as self-adaptive evolution, backpropagation and local search to:
We’ve observed the benefits of AI in drug development, discussed the key challenges in adopting AI and possible ways of facing them, and described some popular AI-based drug discovery use cases.
In a nutshell, AI is capable of making a significant technological contribution which can reshape the whole drug discovery process. However, as many believe, AI-based achievements, perceived as breakthroughs nowadays, will soon become a standard practice for the pharmaceutical industry. The clear and step-by-step AI adoption strategy can open up new horizons for life science companies and help them win in the competitive market.
Kanda brings to the table unique capabilities that help our customers overcome numerous challenges, including AI adoption concerns.
By deploying the latest tools and technologies, such as AI and Machine learning; Big Data; Cloud Engineering and Cloud Deployment; Intelligent Assistants and IoT, we empower Digital Health pioneers and established healthcare delivery organizations at all phases of their software development lifecycle.
Talk to our expert to start your small tech revolution with us!
